Nitrous Oxide-Oxygen
PreclinicalSmall molecule
Nitrous Oxide-Oxygen is one of 40 small molecule programs targeting Acute Pain. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
44 competitors in Depression
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Ketalar
AAultman Health Foundation
Approved
Brintellix
TakedaApproved
Zoloft
VViatris Specialty LLC
Approved
Vraylar
AbbVieApproved
Prozac
VVitae Pharmaceuticals Inc., an Allergan affiliate
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Estrace
Novo NordiskApproved
Spravato
WWim Janssens
Approved
Risperdal
WWim Janssens
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Depression1 trial
Acute Pain1 trial
The 50:50 Nitrous Oxide Challenge: A Prospective Randomised Trial - Needle, Meet Your Match
Active, not recruiting·IInstitute for Oncology and Radiology of Serbia·Preclinical·NCT07618676·62 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nitrous Oxide-Oxygen. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- UUniversity Hospital, Tours